IMS 2022 | Epigenetic dysregulation in ASXL-1-mutant CMML
Moritz Binder
• 26 Aug 2022
Moritz Binder, MD, MPH, Mayo Clinic, Rochester, MN, comments on epigenetic dysregulation and oncogenic gene expression in ASXL-1-mutant chronic myelomonocytic leukemia (CMML), commenting on the results of a study that demonstrated de novo accessibility of high-risk oncogenic enhancer elements in ASXL-1-mutant CMML, and highlighting the possibility of targeting transcription factors that bind to these enhancers. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
